Thomas N. Haag
Plus aucun poste en cours
Profil
Mr. Haag joined UBS Global Asset Management in April 2007.
Prior to joining UBS Global Asset Management, he served as a high yield portfolio manager for SCM Advisors since 2002.
Mr. Haag has held other positions relating to high yield portfolio management and credit research dating back to 1986.
Anciens postes connus de Thomas N. Haag
| Sociétés | Poste | Fin |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Conseiller Juridique Général | 30/09/2009 |
UBS Asset Management (Americas), Inc.
 UBS Asset Management (Americas), Inc. Investment ManagersFinance UBS Asset Management (Americas) LLC (UBS AM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 2000 as UBS Global Asset Management (Americas), Inc. They are a wholly owned subsidiary of UBS Americas, Inc., ultimately owned by UBS Group AG (SIX: UBSG; NYSE: UBS) in Switzerland. UBS AM provides investment products and services to corporate and public pension plans, financial institutions and advisors, central banks, charities, foundations and individual investors around the world. | Portfolio Manager-Fixed Income | 17/10/2008 |
Newfleet Asset Management LLC
 Newfleet Asset Management LLC Investment ManagersFinance Newfleet Asset Management LLC is a SEC-registered investment advisor headquartered in Hartford, Connecticut. They are a wholly-owned subsidiary of Virtus Partners, Inc., which is owned by Virtus Investment Partners, Inc. (NASDAQ: VRTS). The firm was founded in 1989 by Gail Seneca and they were formerly known as SCM Advisors LLC and as Seneca Capital Management LLC. Newfleet Asset Management provides investment management services to foundations, endowments, trusts, pension and profit-sharing plans, corporations, public funds, multi-employer plans, open-end investment companies, closed-end funds, Exchanged Traded Funds, UCITS, registered investment advisers, a CDO and a CLO which are considered private clients. | Portfolio Manager-Fixed Income | 31/03/2007 |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/03/2007 |
Formation de Thomas N. Haag
| University of California, Los Angeles | Doctorate Degree |
| George Washington University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Newfleet Asset Management LLC
Newfleet Asset Management LLC Investment ManagersFinance Newfleet Asset Management LLC is a SEC-registered investment advisor headquartered in Hartford, Connecticut. They are a wholly-owned subsidiary of Virtus Partners, Inc., which is owned by Virtus Investment Partners, Inc. (NASDAQ: VRTS). The firm was founded in 1989 by Gail Seneca and they were formerly known as SCM Advisors LLC and as Seneca Capital Management LLC. Newfleet Asset Management provides investment management services to foundations, endowments, trusts, pension and profit-sharing plans, corporations, public funds, multi-employer plans, open-end investment companies, closed-end funds, Exchanged Traded Funds, UCITS, registered investment advisers, a CDO and a CLO which are considered private clients. | Finance |
UBS Asset Management (Americas), Inc.
UBS Asset Management (Americas), Inc. Investment ManagersFinance UBS Asset Management (Americas) LLC (UBS AM) is a SEC-registered investment advisor headquartered in New York City. The firm was founded in 2000 as UBS Global Asset Management (Americas), Inc. They are a wholly owned subsidiary of UBS Americas, Inc., ultimately owned by UBS Group AG (SIX: UBSG; NYSE: UBS) in Switzerland. UBS AM provides investment products and services to corporate and public pension plans, financial institutions and advisors, central banks, charities, foundations and individual investors around the world. | Finance |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | Health Technology |
